Clinical trials: Cancer Patients and Physical Activity
Advanced Solid Tumor
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors
- Trial name
- NCT06035744
- Testing
- CLN-617, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Cullinan Therapeutics Inc.
Solid Tumors
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally…
- Trial name
- NCT05387265
- Testing
- CX-904
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- CytomX Therapeutics
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB
Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients
Trial Phase: Pilot Indication: Stage IIIB/IV NSCLC Primary Objective: To assess the feasibility and tolerability of exercise training during palliative chemotherapy.
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer Metastatic
- Trial name
- EMBRACE (NCT03334071)
- Testing
- Exercise
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
PD-1 Antibodies, Exercise
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
Checkpoint inhibitors like the PD-1 antibodies Pembrolizumab and Nivolumab represent standard of care for patients with metastasized melanoma.
- Conditions
- PD-1 Antibodies, Exercise, Melanoma
- Trial name
- Sportivumab (NCT03171064)
- Testing
- Resistance and Endurance Exercise
- Where
- Germany
- Volunteers
- 39 people
- Sponsor
- University Hospital Heidelberg
Carcinoma, Non-Small-Cell Lung
JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure
This Phase 1 study will evaluate the safety, maximum tolerated dose, recommended Phase 2 dose, and preliminary antitumor activity of JIN-A02 in combination with amivantamab in participants with advanced EGFR-mutant non-small cell…
- Trial name
- NCT07798921
- Testing
- JIN-A02 in Combination with Amivantamab
- Volunteers
- 36 people
- Sponsor
- Yonsei University
Head and Neck Neoplasms
Rehabilitation for Head and Neck Cancer
Patients treated for head and neck cancer (HNC) suffer from severe side-effects such as pain and difficulties in swallowing, often leading to weight loss.
- Trial name
- NCT02439892
- Testing
- Exercise and nutrition during radiotherapy, Multidimensional rehabilitation after radiotherapy
- Where
- 2 sites in Norway
- Volunteers
- 41 people
- Sponsor
- Norwegian University of Science and Technology
Bladder Cancer, Urothelial Carcinoma
Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study
The purpose of this study is to explore the feasibility and efficacy of a 12-week, home-based exercise program in bladder cancer patients undergoing curative intent neoadjuvant chemotherapy and RC.
- Trial name
- NCT04223063
- Testing
- Exercise program
- Volunteers
- 20 people
- Sponsor
- Ross Mason
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
This is a Phase 1a/1b, multicenter, open-label, first-in-human (FIH) study with MX006 treatment in patients with selected tumor types known to express B7-H3.
- Trial name
- NCT07807241
- Testing
- MX006
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 120 people
- Sponsor
- Myricx Pharma Limited
Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer
A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid Tumors
The purpose of this First-in-Human, Phase 1 study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of MC001 in adults with advanced or…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid Tumors
- Trial name
- NCT07909356
- Testing
- MC001
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Medicovestor, Inc
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT07261631
- Testing
- 68Ga-NNS309, 177Lu-DFC413
- Where
- 9 sites in United States, Canada and 5 more
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT01792687
- Testing
- ARN-509, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Advanced Solid Tumors, Lymphoma
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
This is a first-time-in-human (FTIH), Phase 1 study to determine the safety, tolerability, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of AZD0466 in patients with solid tumors…
- Conditions
- Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT04214093
- Testing
- AZD0466
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Breast Cancer, Paclitaxel Adverse Reaction
Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.
This study looks into how a common breast cancer treatment, paclitaxel, can sometimes cause severe side effects that make it hard for patients to continue treatment.
- Conditions
- Breast Cancer, Paclitaxel Adverse Reaction, Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity
- Trial name
- PABTOX (NCT06387901)
- Testing
- Paclitaxel Chemotherapy
- Where
- 2 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Universitair Ziekenhuis Brussel
Breast Cancer
Effect of Physical Activity in Patients With Breast Cancer.
Every year in France, there are approximately 58,000 new cases of breast cancer, which is the leading cancer in women according to the National Cancer Institute.
- Trial name
- APACAM (NCT05523063)
- Testing
- Quality of life questionnaire
- Where
- France
- Sponsor
- Hospices Civils de Lyon
Hormone Refractory Prostate Cancer
Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer
Docetaxel and sunitinib will be compared to docetaxel for their effect on CEC/CEP spikes induced by docetaxel in HRPC patients
- Trial name
- NCT00795171
- Testing
- Docetaxel * Sunitinib, Docetaxel
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
The purpose of this phase 1 study is to evaluate the safety and anti-tumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in participants with Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or…
- Conditions
- Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03685344
- Testing
- Loncastuximab Tesirine and Durvalumab
- Where
- 14 sites in United States, Spain
- Volunteers
- 13 people
- Sponsor
- ADC Therapeutics S.A.
Prostate Cancer, Prostate Ectomy
Effects of Kieser Resistance Training Plus Kieser Pelvic Floor Training vs. Kieser Resistance Training Plus Traditional Pelvic Floor Exercise on Urinary Incontinence in Prostate Cancer Patients After Radical Prostatectomy
Surgical removal of the prostate (radical prostatectomy) is the most common therapy in prostate cancer patients. However, urinary incontinence often occurs as a side effect.
- Conditions
- Prostate Cancer, Prostate Ectomy, Pelvic Floor Disorders, Incontinence, Urinary
- Trial name
- RECON (NCT06206993)
- Testing
- Resistance training including the Kieser A5 pelvic floor trainer, Resistance training without pelvic floor biofeedback Kieser A5 pelvic floor trainer
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- University Hospital Heidelberg
Fallopian Tube Cancer, Ovarian Cancer
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
RATIONALE: Estrogen may cause the growth of ovarian cancer cells. Hormone therapy using tamoxifen may fight ovarian cancer by blocking the use of estrogen by the tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00305838
- Testing
- tamoxifen citrate, diagnostic laboratory biomarker analysis
- Where
- 24 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
Lung Neoplasm
Compare the Effects of Preoperative Pulmonary Rehabilitation Exercises on Postoperative Anxiety and Muscle Strength
Lung cancer, tracheal and bronchial cancers have long been the leading cause of cancer mortality in Taiwan. According to statistics, about 40% of newly diagnosed lung cancers are treated with surgery as the primary treatment.
- Trial name
- NCT06542055
- Testing
- Preoperative and postoperative pulmonary rehabilitation exercise, Preoperative education and postoperative exercise
- Where
- Taiwan
- Volunteers
- 86 people
- Sponsor
- National Taiwan University Hospital
Advanced Cancer, Metastatic Solid Tumor
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
The main objective for part 1a of the study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of oral TACH101…
- Conditions
- Advanced Cancer, Metastatic Solid Tumor, Solid Tumor
- Trial name
- NCT05076552
- Testing
- TACH101
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tachyon Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.